Cardiac Manifestations in Systemic Lupus Erythematosus: Clinical Correlates of Subclinical Echocardiographic Features
- PMID: 30756081
- PMCID: PMC6348873
- DOI: 10.1155/2019/2437105
Cardiac Manifestations in Systemic Lupus Erythematosus: Clinical Correlates of Subclinical Echocardiographic Features
Abstract
Objectives: This study aims to correlate subclinical echocardiographic features with the clinical, laboratory, and therapeutic profiles of the patients to characterize risks for systemic lupus erythematosus (SLE) cardiac diseases.
Methods: The study included 59 SLE patients. Demographic data, disease characteristics, and current therapies were recorded, and the anthropometric measurements and routine laboratory tests were performed. The disease activity by the SLE Disease Activity Index-2K (SLEDAI2K) and the presence of metabolic syndrome (MetS) were assessed. Two-dimensional echocardiography was performed.
Results: The mean age of the patients was 31.3 ± 10.5 years, and the disease duration was 5.18 ± 4.1 years. 86.4% of the patients were females. Cardiac presentations by echocardiography were mainly mitral regurgitation (33.9%), tricuspid regurgitation (32.2%), mitral thickening (18.6%), aortic thickening (13.6%), pericardial effusion (13.6%), and pulmonary hypertension (8.5%) in order of frequency. The frequency of different echocardiographic findings with respect to other clinical phenotypes showed peaks with renal disease, MetS, and leukopenia. Components of MetS (triglycerides, high systolic blood pressure) and avascular necrosis were significant predictors for pericardial diseases (OR=1.011 CI 95% 1-1.022, p=0.046, OR=1.157 CI 95% 1.025-1.307, p=0.018, and OR=74.78 CI 95% 2.52-2215.76, p=0.013, respectively), and it is likely that hydroxychloroquine was protective against them. Age of the patients was a significant predictor for tricuspid regurgitation (OR=1.063 CI 95% 1.004-1.126, p=0.036). Mucosal ulcers were negative predictors for mitral thickening and regurgitation (OR=0.2 CI 95% 0.059-0.673, p=0.009). The use of corticosteroids appeared to protect against a number of valve lesions especially tricuspid regurgitation (OR=0.299 CI 95% 0.088-1.019, p=0.054).
Conclusion: This study highlighted different echocardiographic features and identified clinical predictors of different cardiac pathologies aiming to determine patients at risk and improve the prognosis of SLE cardiac diseases.
Figures


Similar articles
-
Echocardiographic findings in asymptomatic systemic lupus erythematosus patients.Clin Rheumatol. 2017 Mar;36(3):563-568. doi: 10.1007/s10067-016-3486-4. Epub 2016 Nov 19. Clin Rheumatol. 2017. PMID: 27866289
-
Is the heart affected in primary Sjögren's syndrome? An echocardiographic study.Clin Exp Rheumatol. 2008 Jan-Feb;26(1):109-12. Clin Exp Rheumatol. 2008. PMID: 18328155
-
Pericardial effusion and mitral valve involvement in systemic lupus erythematosus. Echocardiographic study.Ann Rheum Dis. 1977 Aug;36(4):349-53. doi: 10.1136/ard.36.4.349. Ann Rheum Dis. 1977. PMID: 901032 Free PMC article.
-
[Cardiac and cardiopulmonary changes in systemic lupus erythematosus].Orv Hetil. 1989 Jan 29;130(5):215-9. Orv Hetil. 1989. PMID: 2644607 Review. Hungarian.
-
A Meta-analysis and Systematic Review of Valvular Heart Disease in Systemic Lupus Erythematosus and Its Association With Antiphospholipid Antibodies.J Clin Rheumatol. 2021 Dec 1;27(8):e525-e532. doi: 10.1097/RHU.0000000000001464. J Clin Rheumatol. 2021. PMID: 32558678
Cited by
-
Systemic lupus erythematosus with hypothyroidism as the initial clinical manifestation: A case report.Exp Ther Med. 2020 Aug;20(2):996-1002. doi: 10.3892/etm.2020.8788. Epub 2020 May 25. Exp Ther Med. 2020. PMID: 32742342 Free PMC article.
-
Analysis of multiple organ damage and clinical immunological characteristics in systemic lupus erythematosus patients with hematologic involvement.Int J Med Sci. 2021 May 1;18(12):2624-2629. doi: 10.7150/ijms.48997. eCollection 2021. Int J Med Sci. 2021. PMID: 34104094 Free PMC article.
-
Effusive-constrictive pericarditis as first manifestation of late-onset systemic lupus erythematosus: an atypical case with grave prognosis.Egypt Heart J. 2023 Apr 20;75(1):30. doi: 10.1186/s43044-023-00353-6. Egypt Heart J. 2023. PMID: 37079144 Free PMC article.
-
Clinical characteristics and risk factors of cardiovascular disease in systemic lupus erythematosus patients.Heart Vessels. 2025 Jul;40(7):665-675. doi: 10.1007/s00380-024-02508-0. Epub 2024 Dec 24. Heart Vessels. 2025. PMID: 39719523
-
Hematological factors associated with immunity, inflammation, and metabolism in patients with systemic lupus erythematosus: Data from a Zhuang cohort in Southwest China.J Clin Lab Anal. 2020 Jun;34(6):e23211. doi: 10.1002/jcla.23211. Epub 2020 Jan 24. J Clin Lab Anal. 2020. PMID: 31978275 Free PMC article.
References
-
- Manzi S., Meilahn E. N., Rairie J. E., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. American Journal of Epidemiology. 1997;145(5):408–415. doi: 10.1093/oxfordjournals.aje.a009122. - DOI - PubMed
-
- Esdaile J. M., Abrahamowicz M., Grodzicky T., et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis & Rheumatology. 2001;44(10):2331–2337. doi: 10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical